Abstract
Umbilical cord blood (UCB) has become an important source of hematopoietic stem cell transplant (HSCT) for hematologic malignancies in adults. Its ready availability, allowance of higher HLA disparity and lower incidence of graft-versus-host disease (GVHD) makes it a very attractive source especially for minority populations. The major limitation to a wider use of this source of HSCT is the relative low number of progenitor cells in the graft. For this reason, adult UCB transplants are usually associated with delayed engraftment and increased rates of infectious complications. CB ex vivo expansion holds the promise of delivering higher cell doses and improved outcomes. Here we discuss different methods of expansion, their shortcomings and future directions.
Original language | English (US) |
---|---|
Pages (from-to) | 245-257 |
Number of pages | 13 |
Journal | Best Practice and Research: Clinical Haematology |
Volume | 23 |
Issue number | 2 |
DOIs | |
State | Published - Jun 2010 |
Keywords
- ex vivo expansion
- immune reconstitution
- umbilical cord blood transplant
ASJC Scopus subject areas
- Oncology
- Clinical Biochemistry